Search

Your search keyword '"Koopmans, Marion PG [0000-0002-5204-2312]"' showing total 2 results
Start Over Author "Koopmans, Marion PG [0000-0002-5204-2312]"
2 results on '"Koopmans, Marion PG [0000-0002-5204-2312]"'

1. Antigenic cartography of SARS-CoV-2 reveals that Omicron BA.1 and BA.2 are antigenically distinct

Author

Anna Z. Mykytyn, Melanie Rissmann, Adinda Kok, Miruna E. Rosu, Debby Schipper, Tim I. Breugem, Petra B. van den Doel, Felicity Chandler, Theo Bestebroer, Maurice de Wit, Martin E. van Royen, Richard Molenkamp, Bas B. Oude Munnink, Rory D. de Vries, Corine GeurtsvanKessel, Derek J. Smith, Marion P. G. Koopmans, Barry Rockx, Mart M. Lamers, Ron A. M. Fouchier, Bart L. Haagmans, Mykytyn, Anna Z [0000-0001-7188-6871], Rissmann, Melanie [0000-0002-5298-5919], Kok, Adinda [0000-0003-3635-7952], Rosu, Miruna E [0000-0003-3469-7822], Schipper, Debby [0000-0001-6449-4765], Breugem, Tim I [0000-0002-5558-7043], van den Doel, Petra B [0000-0002-5735-5537], Chandler, Felicity [0000-0002-3465-6409], de Wit, Maurice [0000-0003-0449-8822], van Royen, Martin E [0000-0002-6814-0996], Molenkamp, Richard [0000-0002-9004-3850], Oude Munnink, Bas B [0000-0002-9394-1189], de Vries, Rory D [0000-0003-2817-0127], GeurtsvanKessel, Corine [0000-0002-7678-314X], Smith, Derek J [0000-0002-2393-1890], Koopmans, Marion PG [0000-0002-5204-2312], Rockx, Barry [0000-0003-2463-027X], Lamers, Mart M [0000-0002-1431-4022], Fouchier, Ron AM [0000-0001-8095-2869], Haagmans, Bart L [0000-0001-6221-2015], Apollo - University of Cambridge Repository, Virology, Neurology, and Pathology

Subjects
SDG 3 - Good Health and Well-being, SARS-CoV-2, Cricetinae, Immune Sera, Immunology, Animals, COVID-19, Humans, General Medicine, Cell Line
Abstract

The emergence and rapid spread of SARS-CoV-2 variants may affect vaccine efficacy substantially. The Omicron variant termed BA.2, which differs substantially from BA.1 based on genetic sequence, is currently replacing BA.1 in several countries, but its antigenic characteristics have not yet been assessed. Here, we used antigenic cartography to quantify and visualize antigenic differences between early SARS-CoV-2 variants (614G, Alpha, Beta, Gamma, Zeta, Delta, and Mu) using hamster antisera obtained after primary infection. We first verified that the choice of the cell line for the neutralization assay did not affect the topology of the map substantially. Antigenic maps generated using pseudo-typed SARS-CoV-2 on the widely used VeroE6 cell line and the human airway cell line Calu-3 generated similar maps. Maps made using authentic SARS-CoV-2 on Calu-3 cells also closely resembled those generated with pseudo-typed viruses. The antigenic maps revealed a central cluster of SARS-CoV-2 variants, which grouped on the basis of mutual spike mutations. Whereas these early variants are antigenically similar, clustering relatively close to each other in antigenic space, Omicron BA.1 and BA.2 have evolved as two distinct antigenic outliers. Our data show that BA.1 and BA.2 both escape vaccine-induced antibody responses as a result of different antigenic characteristics. Thus, antigenic cartography could be used to assess antigenic properties of future SARS-CoV-2 variants of concern that emerge and to decide on the composition of novel spike-based (booster) vaccines.

Published
2022

2. Defining the risk of SARS-CoV-2 variants on immune protection

Author

Marciela M. DeGrace, Elodie Ghedin, Matthew B. Frieman, Florian Krammer, Alba Grifoni, Arghavan Alisoltani, Galit Alter, Rama R. Amara, Ralph S. Baric, Dan H. Barouch, Jesse D. Bloom, Louis-Marie Bloyet, Gaston Bonenfant, Adrianus C. M. Boon, Eli A. Boritz, Debbie L. Bratt, Traci L. Bricker, Liliana Brown, William J. Buchser, Juan Manuel Carreño, Liel Cohen-Lavi, Tamarand L. Darling, Meredith E. Davis-Gardner, Bethany L. Dearlove, Han Di, Meike Dittmann, Nicole A. Doria-Rose, Daniel C. Douek, Christian Drosten, Venkata-Viswanadh Edara, Ali Ellebedy, Thomas P. Fabrizio, Guido Ferrari, Will M. Fischer, William C. Florence, Ron A. M. Fouchier, John Franks, Adolfo García-Sastre, Adam Godzik, Ana Silvia Gonzalez-Reiche, Aubree Gordon, Bart L. Haagmans, Peter J. Halfmann, David D. Ho, Michael R. Holbrook, Yaoxing Huang, Sarah L. James, Lukasz Jaroszewski, Trushar Jeevan, Robert M. Johnson, Terry C. Jones, Astha Joshi, Yoshihiro Kawaoka, Lisa Kercher, Marion P. G. Koopmans, Bette Korber, Eilay Koren, Richard A. Koup, Eric B. LeGresley, Jacob E. Lemieux, Mariel J. Liebeskind, Zhuoming Liu, Brandi Livingston, James P. Logue, Yang Luo, Adrian B. McDermott, Margaret J. McElrath, Victoria A. Meliopoulos, Vineet D. Menachery, David C. Montefiori, Barbara Mühlemann, Vincent J. Munster, Jenny E. Munt, Manoj S. Nair, Antonia Netzl, Anna M. Niewiadomska, Sijy O’Dell, Andrew Pekosz, Stanley Perlman, Marjorie C. Pontelli, Barry Rockx, Morgane Rolland, Paul W. Rothlauf, Sinai Sacharen, Richard H. Scheuermann, Stephen D. Schmidt, Michael Schotsaert, Stacey Schultz-Cherry, Robert A. Seder, Mayya Sedova, Alessandro Sette, Reed S. Shabman, Xiaoying Shen, Pei-Yong Shi, Maulik Shukla, Viviana Simon, Spencer Stumpf, Nancy J. Sullivan, Larissa B. Thackray, James Theiler, Paul G. Thomas, Sanja Trifkovic, Sina Türeli, Samuel A. Turner, Maria A. Vakaki, Harm van Bakel, Laura A. VanBlargan, Leah R. Vincent, Zachary S. Wallace, Li Wang, Maple Wang, Pengfei Wang, Wei Wang, Scott C. Weaver, Richard J. Webby, Carol D. Weiss, David E. Wentworth, Stuart M. Weston, Sean P. J. Whelan, Bradley M. Whitener, Samuel H. Wilks, Xuping Xie, Baoling Ying, Hyejin Yoon, Bin Zhou, Tomer Hertz, Derek J. Smith, Michael S. Diamond, Diane J. Post, Mehul S. Suthar, Ghedin, Elodie [0000-0002-1515-725X], Frieman, Matthew B [0000-0003-0107-0775], Krammer, Florian [0000-0003-4121-776X], Grifoni, Alba [0000-0002-2209-5966], Alter, Galit [0000-0002-7680-9215], Amara, Rama R [0000-0002-6309-6797], Baric, Ralph S [0000-0001-6827-8701], Barouch, Dan H [0000-0001-5127-4659], Bloom, Jesse D [0000-0003-1267-3408], Bloyet, Louis-Marie [0000-0002-5648-3190], Boon, Adrianus CM [0000-0002-4700-8224], Bratt, Debbie L [0000-0002-5822-5558], Buchser, William J [0000-0002-6675-6359], Cohen-Lavi, Liel [0000-0001-6909-4779], Dearlove, Bethany L [0000-0003-3653-4592], Drosten, Christian [0000-0001-7923-0519], Edara, Venkata-Viswanadh [0000-0001-9321-7839], Ellebedy, Ali [0000-0002-6129-2532], Fabrizio, Thomas P [0000-0002-8960-0728], Fouchier, Ron AM [0000-0001-8095-2869], García-Sastre, Adolfo [0000-0002-6551-1827], Godzik, Adam [0000-0002-2425-852X], Gonzalez-Reiche, Ana Silvia [0000-0003-3583-4497], Gordon, Aubree [0000-0002-9352-7877], Haagmans, Bart L [0000-0001-6221-2015], Ho, David D [0000-0003-1627-149X], Holbrook, Michael R [0000-0002-0824-2667], Huang, Yaoxing [0000-0001-6270-1644], James, Sarah L [0000-0002-6969-1167], Johnson, Robert M [0000-0002-1976-7688], Jones, Terry C [0000-0003-1120-9531], Joshi, Astha [0000-0003-4914-8228], Kawaoka, Yoshihiro [0000-0001-5061-8296], Kercher, Lisa [0000-0001-6300-0452], Koopmans, Marion PG [0000-0002-5204-2312], Korber, Bette [0000-0002-2026-5757], LeGresley, Eric B [0000-0002-5286-5693], Liebeskind, Mariel J [0000-0003-4595-0651], Liu, Zhuoming [0000-0001-8198-0976], Logue, James P [0000-0002-7410-9741], Luo, Yang [0000-0003-3277-8792], McDermott, Adrian B [0000-0003-0616-9117], Meliopoulos, Victoria A [0000-0003-1442-9177], Menachery, Vineet D [0000-0001-8803-7606], Munster, Vincent J [0000-0002-2288-3196], Nair, Manoj S [0000-0002-5994-3957], Netzl, Antonia [0000-0001-8034-2382], Pekosz, Andrew [0000-0003-3248-1761], Perlman, Stanley [0000-0003-4213-2354], Rockx, Barry [0000-0003-2463-027X], Rolland, Morgane [0000-0003-3650-8490], Rothlauf, Paul W [0000-0002-0941-4467], Scheuermann, Richard H [0000-0003-1355-892X], Schotsaert, Michael [0000-0003-3156-3132], Schultz-Cherry, Stacey [0000-0002-2021-727X], Seder, Robert A [0000-0003-3133-0849], Shabman, Reed S [0000-0003-3272-3484], Shi, Pei-Yong [0000-0001-5553-1616], Simon, Viviana [0000-0002-6416-5096], Thackray, Larissa B [0000-0002-9380-6569], Thomas, Paul G [0000-0001-7955-0256], Trifkovic, Sanja [0000-0002-0710-9514], Türeli, Sina [0000-0001-7342-9295], van Bakel, Harm [0000-0002-1376-6916], VanBlargan, Laura A [0000-0002-8922-8946], Vincent, Leah R [0000-0001-9262-1813], Wallace, Zachary S [0000-0003-0237-501X], Wang, Pengfei [0000-0003-2454-7652], Weaver, Scott C [0000-0001-8016-8556], Webby, Richard J [0000-0002-4397-7132], Weiss, Carol D [0000-0002-9965-1289], Wentworth, David E [0000-0002-5190-980X], Weston, Stuart M [0000-0001-9840-2953], Whelan, Sean PJ [0000-0003-1564-8590], Whitener, Bradley M [0000-0001-6652-0701], Xie, Xuping [0000-0003-0918-016X], Yoon, Hyejin [0000-0002-3344-9096], Hertz, Tomer [0000-0002-0561-1578], Smith, Derek J [0000-0002-2393-1890], Diamond, Michael S [0000-0002-8791-3165], Post, Diane J [0000-0003-3890-9116], Suthar, Mehul S [0000-0002-2686-8380], and Apollo - University of Cambridge Repository

Subjects
Multidisciplinary, COVID-19 Vaccines, Pharmacogenomic Variants, Virulence, SARS-CoV-2, COVID-19, Biological Evolution, Article, United States, SDG 3 - Good Health and Well-being, National Institute of Allergy and Infectious Diseases (U.S.), Animals, Humans, Pandemics
Abstract

The global emergence of many severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants jeopardizes the protective antiviral immunity induced following infection or vaccination. To address the public health threat caused by the increasing SARS-CoV-2 genomic diversity, the National Institute of Allergy and Infectious Diseases (NIAID) within the National Institutes of Health (NIH) established the SARS-CoV-2 Assessment of Viral Evolution (SAVE) program. This effort was designed to provide a real-time risk assessment of SARS-CoV-2 variants potentially impacting transmission, virulence, and resistance to convalescent and vaccine-induced immunity. The SAVE program serves as a critical data-generating component of the United States Government SARS-CoV-2 Interagency Group to assess implications of SARS-CoV-2 variants on diagnostics, vaccines, and therapeutics and for communicating public health risk. Here we describe the coordinated approach used to identify and curate data about emerging variants, their impact on immunity, and effects on vaccine protection using animal models. We report the development of reagents, methodologies, models, and pivotal findings facilitated by this collaborative approach and identify future challenges. This program serves as a template for the response against rapidly evolving pandemic pathogens by monitoring viral evolution in the human population to identify variants that could erode the effectiveness of countermeasures.

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results